Jair Clarke
About Jair Clarke
Independent Class II director at Xponential Fitness since July 2022; age 43. Technology executive with >15 years across product management, digital transformation, cybersecurity, data science, and innovation. Currently CEO and Chief Artificial Intelligence Officer at Laigic.com (joined 2024) and a director at OneMedNet (clinical imaging software). Holds a B.B.A. in Computer Information Systems from the University of Miami . He is an independent NYSE-qualified director at XPOF and serves on multiple board committees, including as chair of Human Capital Management .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Microsoft | Global CTO, Commercial Systems | Joined Aug 2020; previously served before joining Laigic in 2024 | Senior technology leadership at scale |
| The Walt Disney Company | Various technology and business executive positions | 2014–2020 | Digital transformation and operations roles |
| IBM | IT & Business Development Executive | 2007–2014 | Enterprise IT and BD experience |
| Lockheed Martin | Expanding technology responsibilities | 2005–2007 | Engineering/IT exposure |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Laigic.com (advisory/consulting) | CEO & Chief Artificial Intelligence Officer | 2024–present | AI leadership; private firm (governance not disclosed in proxy) |
| OneMedNet (healthcare software) | Director | Not disclosed | Clinical imaging solutions; no interlocks with XPOF disclosed |
Board Governance
- Independence: Determined independent under NYSE rules; no family relationships disclosed. Board currently has seven members; roles of Chair and CEO are separated .
- Committee assignments (2024 activity year):
- Human Capital Management Committee: Chair (approves/oversees executive and director pay; administers equity plans) .
- Audit Committee: Member; committee is fully independent; all members financially literate (audit financial expert designation applies to other members) .
- Nominating & Corporate Governance Committee: Member .
- Attendance and engagement: In 2024 there were 24 board meetings; each director attended at least 75% of board and committee meetings; all directors attended the 2024 annual meeting .
- Risk and controls: Audit Committee oversees financial and cybersecurity risk and reviews related party transactions; HCM Committee assesses pay-related risk; Nominating Committee oversees governance guidelines .
Fixed Compensation
| Year | Fees Earned or Paid in Cash ($) | Notes |
|---|---|---|
| 2023 | 98,515 | Under May 10, 2023 Outside Director Compensation Policy |
| 2024 | 117,050 | Under updated July 1, 2024 Policy |
Policy fee schedule as of July 1, 2024 (relevant to Clarke’s roles):
- Board member: $80,000 annual cash retainer
- Audit Committee member: $12,000
- Human Capital Management Committee chair: $15,000
- Nominating & Corporate Governance Committee member: $8,000
- Non-cash option: directors may elect RSUs in lieu of cash for all/part of retainers
Performance Compensation
| Grant Date | Instrument | Quantity | Grant-Date Fair Value ($) | Vesting | Notes |
|---|---|---|---|---|---|
| May 30, 2024 | RSUs | 9,888 | 92,453 | Eligible to vest May 21, 2025, service-based | Annual director equity grant; time-based, not performance-vested |
- Directors can elect fully vested RSUs in lieu of cash retainers; in 2024 this election was disclosed for Mark Grabowski and Jeffrey Lawrence, not for Clarke .
- Omnibus Incentive Plan applies to non-employee directors; upon a change in control, the committee may continue/assume, substitute, accelerate, or cash-out awards, including determining performance attainment for performance awards (director equity grants are time-based) .
Other Directorships & Interlocks
| Company | Public/Private | Role | Potential Interlock/Conflict |
|---|---|---|---|
| OneMedNet | Not specified in proxy | Director | No related-party transactions with XPOF disclosed |
| Laigic.com | Private | CEO & Chief AI Officer | No related-party transactions with XPOF disclosed |
- Related-person transaction oversight: XPOF’s Audit Committee administers a formal Related Person Transaction Policy for items over $120,000; only transactions described in the proxy would qualify, and none involve Clarke .
Expertise & Qualifications
- Deep technology and AI background (Microsoft CTO role; AI leadership at Laigic) aligned with XPOF’s growing digital and data needs .
- Governance experience across multiple large enterprises (Disney, IBM) and as a public company director (XPOF and OneMedNet) .
- Financial literacy via Audit Committee service; committee meets NYSE and SEC independence and literacy standards .
- Independent status and multi-committee workload (chairing HCM) indicate high governance engagement .
Equity Ownership
| As of March 31, 2025 | Amount | % of Class |
|---|---|---|
| Total beneficial ownership (Class A) | 16,606 | <1% |
| Ownership breakdown | 6,718 shares held directly; 9,888 RSUs vesting within 60 days | — |
| Pledged shares | None disclosed for Clarke in ownership footnotes | — |
| Anti-hedging | Directors prohibited from hedging company stock | — |
Director Compensation – Year-over-Year Mix
| Year | Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| 2023 | 98,515 | 24,079 | 122,594 |
| 2024 | 117,050 | 92,453 | 209,503 |
- Mix shifted toward equity in 2024 following policy update (annual equity value increased to $110,000 and service-based RSUs granted), which can improve alignment but lacks performance conditions at the director level .
Governance Assessment
-
Positives
- Independent director with strong technology/AI credentials; multi-committee service including HCM chair enhances board effectiveness on compensation oversight and talent strategy .
- Audit Committee service supports financial oversight; committee independence and literacy standards met .
- Attendance adequate: at least 75% of applicable meetings in 2024; full board attendance at 2024 annual meeting .
- Anti-hedging policy applies to directors; no share pledging disclosed for Clarke, reducing alignment risk .
-
Watch items
- Director equity is time-based RSUs (no performance-vesting), which aligns ownership but does not directly tie director pay to TSR or operational results; investors may prefer performance-linked elements for executives (less common for directors) .
- The board remains classified (staggered terms), which some governance frameworks view as entrenching; though not specific to Clarke, it affects overall board accountability .
- 2024 financial statement restatement did not trigger clawback recovery; as HCM chair, continued monitoring of compensation risk and clawback policy effectiveness remains important for investor confidence .
-
Red flags
- None specific to Clarke disclosed: no related-party transactions, no Section 16 filing delinquencies for Clarke in 2024 .
Board Governance (Committee Map for Clarke)
| Committee | Role | Key Oversight Areas |
|---|---|---|
| Human Capital Management | Chair | Executive and director compensation; equity plan administration; pay philosophy and incentive plans |
| Audit | Member | Auditor oversight; internal controls; financial/cyber risk; related-party transaction review |
| Nominating & Corporate Governance | Member | Board composition and evaluations; governance policies; code waivers |
Notes on Policies Relevant to Clarke
- Outside Director Compensation Policy (as of July 1, 2024): cash retainers by role; equity grant $110,000; optional RSUs in lieu of cash .
- Omnibus Incentive Plan: applicable to non-employee directors; provides pathways for award treatment upon change in control (including possible acceleration) .
- Related Person Transaction Policy: Audit Committee reviews/approves related-party transactions; no Clarke-related items disclosed .
- Anti-hedging: prohibits directors from hedging XPOF equity; supports alignment .